Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Technosphere Insulin vs Oral Agents in T2DM
NCT00332488Phase 3Completed
- Sponsor
- MannKind
- Start
- Dec 2004
- Primary completion
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of TI-Inhalation Powder B in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by MannKind. Primary endpoint: Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue at 12 weeks. Started Dec 2004; status: completed.
02
Drugs
TI-Inhalation Powder B
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00332488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332488.